Evidence map›Paper›PMID 33863874›Full record

ArticleCell death discovery2021

Azithromycin alleviates systemic lupus erythematosus via the promotion of M2 polarisation in lupus mice.

Jie Wang, Qian Chen, Zhixiong Zhang, Shangshang Wang, Yilun Wang, Mengmeng Xiang, Jun Liang, Jinhua Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jie Wang *Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-9449-7593
Qian Chen *Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-8201-2774
Zhixiong ZhangDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Shangshang WangDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-7257-2444
Yilun WangDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-0584-5083
Mengmeng XiangDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-6752-4827
Jun LiangDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. liangjun1976@medmail.com.cn.ORCID http://orcid.org/0000-0001-5318-4323
Jinhua XuDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. jinhuaxu@fudan.edu.cn.ORCID http://orcid.org/0000-0002-2725-4903
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous study demonstrated that azithromycin could promote alternatively activated (M2) macrophages under lupus conditions in vitro, which might be beneficial for lupus treatment. Thus, the aim of this study was to further confirm whether azithromycin can drive M2 polarisation in lupus and ultimately alleviate systemic lupus erythematosus (SLE) in vivo. Lymphocyte-derived DNA (ALD-DNA)-induced mice (induced lupus model) and MRL-Fas

Identifiers

PMID33863874
PMCPMC8050155
OpenAlexW3155667909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.